Shorts Action: What’s Next for Adaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) After Having More Shares Shorted?

November 23, 2016 - By Marguerite Chambers   ·   0 Comments

Shorts Action: What's Next for Adaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) After Having More Shares Shorted?

The stock of Adaptimmune Therapeutics Plc Ads (NASDAQ:ADAP) registered an increase of 32.34% in short interest. ADAP’s total short interest was 509,100 shares in November as published by FINRA. Its up 32.34% from 384,700 shares, reported previously. With 199,500 shares average volume, it will take short sellers 3 days to cover their ADAP’s short positions. The short interest to Adaptimmune Therapeutics Plc Ads’s float is 2.17%. About 23,496 shares traded hands. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has declined 46.08% since April 21, 2016 and is downtrending. It has underperformed by 51.41% the S&P500.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The company has a market cap of $352.32 million. The Firm is focused on cancer immunotherapy products based on its T-cell receptor platform. It currently has negative earnings. The Firm has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Ratings Coverage

Out of 2 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 1 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 50% are positive. Adaptimmune Therapeutics PLC has been the topic of 2 analyst reports since February 25, 2016 according to StockzIntelligence Inc. As per Thursday, February 25, the company rating was initiated by Citigroup. Bank of America downgraded the stock to “Underperform” rating in Monday, October 24 report.

ADAP Company Profile

Adaptimmune Therapeutics plc, incorporated on December 03, 2014, is a clinical-stage biopharmaceutical company. The Firm is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Firm has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Firm develops TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients.

More news for Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) were recently published by: Marketwatch.com, which released: “Adaptimmune Therapeutics PLC ADR” on April 14, 2015. Quotes.Wsj.com‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on November 29, 2014 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers

Tags:


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>